Titre :

Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial.

Auteur(s) :

Chau, Ian [Auteur]
The Royal Marsden NHS Foundation Trust [London]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Soriano, Andres O. [Auteur]
Arkenau, Hendrik-Tobias [Auteur]
Sarah Cannon Research Institute [Londres]
Cultrera, Jennifer [Auteur]
Santana-Davila, Rafael [Auteur]
University of Washington [Seattle]
Calvo, Emiliano [Auteur]
Zender, Lars [Auteur]
Eberhard Karls Universität Tübingen = University of Tübingen
Bendell, Johanna C. [Auteur]
Sarah Cannon Research Institute [Nashville, Tennessee]
Mi, Gu [Auteur]
Eli Lilly and Company [Indianapolis]
Gao, Ling [Auteur]
Eli Lilly and Company [Indianapolis]
Mcneely, Samuel Clark [Auteur]
Eli Lilly and Company [Indianapolis]
Oliveira, Joana M. [Auteur]
Ferry, David [Auteur]
Herbst, Roy S. [Auteur]
Yale School of Medicine [New Haven, Connecticut] [YSM]
Fuchs, Charles S. [Auteur]
Yale University [New Haven]

Titre de la revue :

Cancers

Nom court de la revue :

Cancers (Basel)

Numéro :

12

Date de publication :

2020-10-24

ISSN :

2072-6694

Mot(s)-clé(s) en anglais :

gastric
gastroesophageal junction adenocarcinoma
pembrolizumab
phase 1b
ramucirumab

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Ramucirumab (anti-VEGFR2) plus pembrolizumab (anti-PD1) demonstrated promising antitumor activity and tolerability among patients with previously treated advanced cancers, supporting growing evidence that combination ...
Lire la suite >Ramucirumab (anti-VEGFR2) plus pembrolizumab (anti-PD1) demonstrated promising antitumor activity and tolerability among patients with previously treated advanced cancers, supporting growing evidence that combination therapies modulating the tumor microenvironment may expand the spectrum of patients who respond to checkpoint inhibitors. Here we present the results of this combination in first-line patients with metastatic G/GEJ cancer. Twenty-eight patients (≥18 years) with no prior systemic chemotherapy in the advanced/metastatic setting received ramucirumab (8 mg/kg days 1 and 8) plus pembrolizumab (200 mg day 1) every 3 weeks as part of JVDF phase 1a/b study. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). Tumors were PD-L1-positive (combined positive score ≥ 1) in 19 and -negative in 6 patients. Eighteen patients experienced grade 3 treatment-related adverse events, most commonly hypertension (14%) and elevated alanine/aspartate aminotransferase (11% each), with no grade 4 or 5 reported. The ORR was 25% (PD-L1-positive, 32%; PD-L1-negative, 17%) with duration of response not reached. PFS was 5.6 months (PD-L1-positive, 8.6 months; PD-L1-negative, 4.3 months), and OS 14.6 months (PD-L1-positive, 17.3 months; PD-L1-negative, 11.3 months). Acknowledging study design limitations, ramucirumab plus pembrolizumab had encouraging durable clinical activity with no unexpected toxicities in treatment-naïve biomarker-unselected metastatic G/GEJ cancer, and improved outcomes in patients with PD-L1-positive tumors.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2023-11-15T07:57:00Z
2023-12-21T12:56:50Z